R. Roberts

发表

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

A. Lawrie, A. Hill, S. Gilbert, 2019, Vaccines.

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

S. Faust, A. Lawrie, L. Coughlan, 2018, EBioMedicine.

Induction of the vascular endothelial growth factor pathway in the brain of adults with fatal falciparum malaria is a non-specific response to severe disease

H. Turley, N. Day, N. White, 2010, Histopathology.

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

J. Vekemans, S. Faust, A. Lawrie, 2021, Frontiers in Immunology.

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Nguyen H. Tran, A. Lawrie, A. Hill, 2020, The Lancet. Infectious diseases.

Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open- labelled, first-in-human, dose-escalation trial

Nguyen H. Tran, A. Lawrie, A. Hill, 2020 .

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

A. Lawrie, A. Hill, S. Mboup, 2018, The Journal of infectious diseases.

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP

A. Nicosia, S. Faust, A. Lawrie, 2018, Scientific Reports.

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Juliana K. Wambua, J. McCarthy, J. Vekemans, 2017, JCI insight.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2018, npj Vaccines.

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

P. Bejon, S. Sirima, A. Lawrie, 2018, PloS one.

Safety and Immunogenicity of ChAd 63 and MVA ME-TRAP in West African Children and Infants

R. Cortese, A. Nicosia, K. Bojang, 2022 .

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2016, Journal of Infectious Diseases.

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

A. Nicosia, K. Marsh, P. Njuguna, 2015, Science Translational Medicine.

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals

R. Cortese, A. Nicosia, R. Sinden, 2014, The Journal of infectious diseases.

Fatal Plasmodium falciparum Malaria Causes Specific Patterns of Splenic Architectural Disorganization

D. Ferguson, N. Day, N. White, 2005, Infection and Immunity.

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

O. Traoré, H. Tinto, H. Sorgho, 2021, The Lancet.

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.

H. Tinto, H. Sorgho, I. Valéa, 2022, The Lancet. Infectious diseases.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2018, npj Vaccines.

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP

A. Nicosia, S. Faust, A. Lawrie, 2018, Scientific Reports.

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

B. Cissé, B. Faye, R. Cortese, 2017, Frontiers in Immunology.

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.

A. Lawrie, K. Ewer, I. Poulton, 2017, Vaccine.

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies

J. McCarthy, A. Nicosia, T. Otto, 2017, JCI insight.

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

R. Cortese, K. Bojang, S. Sirima, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

B. Cissé, J. Gomis, O. Gaye, 2016, PloS one.

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

R. Cortese, A. Nicosia, K. Bojang, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

R. Cortese, A. Nicosia, K. Bojang, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

R. Cortese, A. Nicosia, K. Bojang, 2013, PloS one.

Prime and target immunization protects against liver-stage malaria in mice

R. Germain, C. Janse, B. Angus, 2018, Science Translational Medicine.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Edward Wright, Thomas Strecker, Paul Chaplin, 2015, The New England journal of medicine.

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Young Chan Kim, A. Lawrie, A. Hill, 2021, Nature Communications.

Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe

S. Hoffman, R. Longley, A. Lawrie, 2013, PloS one.

Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.

J. McCarthy, N. Waters, G. Cooke, 2016, The Journal of infectious diseases.

Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers

S. Sirima, B. Angus, A. Lawrie, 2019 .

Host vascular endothelial growth factor is trophic for Plasmodium falciparum-infected red blood cells.

D. Ferguson, N. Day, N. White, 2008, Asian Pacific journal of allergy and immunology.

High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso

O. Traoré, H. Tinto, H. Sorgho, 2021 .

HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT

J. Baum, A. Blagborough, S. Faust, 2017 .

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

A. Lawrie, A. Hill, J. Hermon-Taylor, 2019, Vaccines.